<DOC>
	<DOCNO>NCT01221441</DOCNO>
	<brief_summary>The purpose study see safely regenerate cartilage without invasive surgery use biologic product call TissueGene-C .</brief_summary>
	<brief_title>Study TG-C Patients With Grade 3 Degenerative Joint Disease Knee</brief_title>
	<detailed_description>Protocol TGC09201 multi-center , double-blind , placebo-controlled , randomize study . A total one hundred ( 100 ) adult grade 3 chronic degenerative joint disease ( DJD ) knee joint ( determined radiographic examination ) enrol study . TissueGene-C administered intra-articularly via x-ray guidance . TissueGene-C administer dose 3 x 10e7 cell . Patients receive control treatment receive single normal saline injection . The objective study : 1 . Evaluate efficacy TissueGene-C regard knee functionality symptom knee osteoarthritis include pain . 2 . Evaluate safety administration single intra-articular dose TissueGene-C evidence observation injection site irritation abnormality , incidence severity adverse event , change physical examination finding laboratory test , include immune analysis . 3 . Evaluate incidence dose analgesia and/or anti-inflammatory medication . 4 . Evaluate regeneration hyaline cartilage determine 3T magnetic resonance imaging ( MRI ) . 5 . Evaluate distribution hChonJb # 7 cell injection site . 6 . Evaluate efficacy TissueGene-C evaluate need total knee arthroplasty treatment</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<criteria>1 . Male Female subject 2 . Age 18 70 year 3 . In general good health evidence physical examination , normal hematology , serum chemistry , urinalysis screen laboratory result , negative history significant organ system disorder . All laboratory value must within 20 % normal range . 1 . Body Mass Index ( BMI ) '18.5 45.5 ' . The applied scale men woman . 2 . Blood Pressure measurement Systolic Blood Pressure 90160mm . Hg , Diastolic Blood Pressure 5090mm.Hg , 4 . Patients Grade 3 chronic osteoarthritis knee determine Radiographic Criteria Kellgren Lawrence . 5 . Symptom pain four ( 4 ) consecutive month intensity ≥ 40 ≤ 90 100mm scale . 6 . Patients clear use protocol specify equipment : 3T MRI . 7 . Patients provide write informed consent nature study fully explain understood patient . 1 . Age 71 old 2 . Patients abnormal hematology , serum chemistry , urinalysis screen laboratory result . 3 . Patients take nonsteroidal antiinflammatory medication within 14 day baseline visit unless wash per section 3.6.4 . 4 . Patients take steroidal antiinflammatory medication within 2 month baseline visit . 5 . Patients recent ( within 1 year ) history drug abuse and/or positive urine drug test time screen . 6 . Patients receive injection treat knee within 2 month prior study entry 7 . Patients contraindicate 3T MRI . 8 . Patients pregnant currently breastfeed child . 9 . Patients systemic , rheumatic inflammatory disease knee chondrocalcinosis , hemochromatosis , inflammatory arthritis , necrosis femoral condyle , arthropathy knee associate juxtaarticular Paget 's disease femur tibia , ochronosis , hemophilic arthropathy , infectious arthritis , Charcot 's knee joint , villonodular synovitis , synovial chondromatosis , and/or history inflammatory arthropathy . 10 . Patients ongoing infectious disease , include HIV hepatitis B C. 11 . Patients clinically significant cardiovascular , renal , hepatic , endocrine disease , cancer , Type I diabetes . 12 . Patients participate study experimental drug medical device within 30 day study entry . 13 . Patients unable comply requisite study followup able complete followup office visit 3T MRI exam .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Cartilage</keyword>
	<keyword>Knee</keyword>
	<keyword>Osteoarthritis</keyword>
</DOC>